FDA Deficiency Letters in Generic Drug Applications: Common Findings and How to Fix Them
Discover the most common FDA deficiency letters in generic drug applications. Learn why ANDAs fail, from impurity issues to bioequivalence gaps, and how to avoid costly delays.
Aug 11 2026